Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial.

Caterson ID, Finer N, Coutinho W, Van Gaal LF, Maggioni AP, Torp-Pedersen C, Sharma AM, Legler UF, Shepherd GM, Rode RA, Perdok RJ, Renz CL, James WP; SCOUT Investigators.

Diabetes Obes Metab. 2012 Jun;14(6):523-30. doi: 10.1111/j.1463-1326.2011.01554.x. Epub 2012 Jan 18.

PMID:
22192338
2.

Efficacy and safety of ABT-874, a monoclonal anti-interleukin 12/23 antibody, for the treatment of chronic plaque psoriasis: 36-week observation/retreatment and 60-week open-label extension phases of a randomized phase II trial.

Kimball AB, Gordon KB, Langley RG, Menter A, Perdok RJ, Valdes J; ABT-874 Study Investigators.

J Am Acad Dermatol. 2011 Feb;64(2):263-74. doi: 10.1016/j.jaad.2010.01.030. Epub 2010 Dec 9.

PMID:
21145618
3.

Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT.

Gladman DD, Mease PJ, Choy EH, Ritchlin CT, Perdok RJ, Sasso EH.

Arthritis Res Ther. 2010;12(3):R113. doi: 10.1186/ar3049. Epub 2010 Jun 10.

4.

Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT).

Mease PJ, Ory P, Sharp JT, Ritchlin CT, Van den Bosch F, Wellborne F, Birbara C, Thomson GT, Perdok RJ, Medich J, Wong RL, Gladman DD.

Ann Rheum Dis. 2009 May;68(5):702-9. doi: 10.1136/ard.2008.092767. Epub 2008 Aug 6.

5.

Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy.

Genovese MC, Mease PJ, Thomson GT, Kivitz AJ, Perdok RJ, Weinberg MA, Medich J, Sasso EH; M02-570 Study Group.

J Rheumatol. 2007 May;34(5):1040-50. Epub 2007 Apr 15. Erratum in: J Rheumatol. 2007 Jun;34(6):1439.

PMID:
17444593
6.

Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial.

Gladman DD, Mease PJ, Ritchlin CT, Choy EH, Sharp JT, Ory PA, Perdok RJ, Sasso EH.

Arthritis Rheum. 2007 Feb;56(2):476-88.

7.
8.

Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial.

Mease PJ, Gladman DD, Ritchlin CT, Ruderman EM, Steinfeld SD, Choy EH, Sharp JT, Ory PA, Perdok RJ, Weinberg MA; Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group.

Arthritis Rheum. 2005 Oct;52(10):3279-89.

Supplemental Content

Loading ...
Support Center